Show Summary Details
Page of

Routine Long-Term Epilepsy Follow-up 

Routine Long-Term Epilepsy Follow-up
Routine Long-Term Epilepsy Follow-up

Na Tosha N. Gatson

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 03 December 2021

The chapter on teratogenic medication examines key clinical considerations for evaluating and treating reproductive-aged women on therapies with high reproductive risk factors. Physicians should frequently reexamine the appropriateness of using potentially harmful therapies in their patient population. The U.S. Food and Drug Administration (FDA) recently revised the “Pregnancy and Lactation Labeling Rule” to assist providers in evaluating drug risks to pregnant or nursing mothers. Reproductive-aged women on anti-epileptic drugs (AEDs) might experience challenges related to medication noncompliance, unknown drug–drug interactions, and unintended pregnancy. Therefore, it is important for clinicians to frequently educate and interview their patients about reproductive planning, prevention, and medication risks. Modifying, supplementing, or discontinuing medical therapy when appropriate should also be addressed at each visit.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.